{"nctId":"NCT02275780","briefTitle":"Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)","startDateStruct":{"date":"2014-12-01","type":"ACTUAL"},"conditions":["HIV-1"],"count":769,"armGroups":[{"label":"Doravirine 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Doravirine","Drug: TRUVADA™ or EPZICOM™/KIVEXA™"]},{"label":"Darunavir 800 mg and Ritonavir 100 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Doravirine","Drug: Darunavir","Drug: Ritonavir","Drug: TRUVADA™ or EPZICOM™/KIVEXA™"]}],"interventions":[{"name":"Doravirine","otherNames":[]},{"name":"Darunavir","otherNames":[]},{"name":"Ritonavir","otherNames":[]},{"name":"TRUVADA™ or EPZICOM™/KIVEXA™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is HIV-1 positive and has HIV treatment indicated based on physician assessment.\n* Has received no (0 days of) antiretroviral therapy (ART), including investigational antiretroviral agents.\n* Is considered clinically stable with no signs or symptoms of active infection for at least 2 weeks prior to the start of treatment.\n* Female is highly unlikely to become pregnant, or male is highly unlikely to impregnate a partner because they are not of reproductive potential, or agree to practice abstinence or use acceptable contraception for up to 14 days after the last dose of study drug.\n* Eligibility for the Study Extension 1 at the Week 96 visit: 1) completed the Week 96 visit, 2) derived benefit from participation through Week 96 in the opinion of the investigator, 3) is a clinically-appropriate candidate for an additional 96 weeks of treatment with the Study Extension regimen.\n* Eligibility for the Study Extension 2 at the Week 192 visit: 1) completed the Week 192 visit, 2) derived benefit from participation through Week 192 in the opinion of the investigator, 3) is a clinically-appropriate candidate for 96 weeks of treatment with the Study Extension regimen.\n\nExclusion Criteria:\n\n* Uses or has had a recent history of using recreational or illicit drugs.\n* Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1.\n* Has documented or known resistance to study drugs including doravirine, darunavir, ritonavir, emtricitabine, tenofovir, abacavir and/or lamivudine.\n* Has participated in a study with an investigational compound/device within the prior month, or anticipates doing so during this study.\n* Has used systemic immunosuppressive therapy or immune modulators within the prior 30 days, or anticipates doing so during this study.\n* Has significant hypersensitivity or other contraindication to any of the components of the study drugs.\n* Has a current (active) diagnosis of acute hepatitis due to any cause.\n* Is pregnant, breastfeeding or expecting to conceive at any time during the study.\n* Female who expects to donate eggs, or male who expects to donate sperm at any time during the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48","description":"The percentage of participants in each arm achieving HIV-1 RNA levels \\<50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) \"snapshot\" approach and all missing data were considered treatment failures, regardless of the reason.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.8","spread":null},{"groupId":"OG001","value":"79.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 96","description":"The percentage of participants in each arm achieving HIV-1 RNA levels \\<50 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) \"snapshot\" approach and all missing data were considered treatment failures, regardless of the reason.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":null},{"groupId":"OG001","value":"66.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean CD4+ T-cell Count at Week 48","description":"CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192.7","spread":null},{"groupId":"OG001","value":"185.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean CD4+ T-cell Count at Week 96","description":"CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"224.1","spread":null},{"groupId":"OG001","value":"206.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48","description":"Serum LDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid-lowering therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.10","spread":"28.61"},{"groupId":"OG001","value":"91.76","spread":"30.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.51","spread":"20.64"},{"groupId":"OG001","value":"9.92","spread":"27.31"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48","description":"Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113.34","spread":"34.25"},{"groupId":"OG001","value":"114.44","spread":"35.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.30","spread":"23.28"},{"groupId":"OG001","value":"13.75","spread":"31.08"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 48","description":"Serum HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.58","spread":"12.99"},{"groupId":"OG001","value":"43.27","spread":"13.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.94","spread":"10.66"},{"groupId":"OG001","value":"4.15","spread":"11.01"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Fasting Total Cholesterol at Week 48","description":"Serum total cholesterol was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"156.92","spread":"35.82"},{"groupId":"OG001","value":"157.71","spread":"37.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.37","spread":"25.47"},{"groupId":"OG001","value":"17.90","spread":"33.95"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Fasting Triglyceride at Week 48","description":"Serum triglyceride was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111.16","spread":"75.31"},{"groupId":"OG001","value":"117.02","spread":"97.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.14","spread":"68.81"},{"groupId":"OG001","value":"21.97","spread":"92.59"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Adverse Event","description":"An adverse event (AE) is defined as any untoward medical occurrence in a study participant and which does not necessarily have to have a causal relationship to treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the study treatment or protocol-specified procedure, whether or not considered related to study treatment or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study treatment is also an AE. The percentage of participants with any AE was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.6","spread":null},{"groupId":"OG001","value":"82.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Serious Adverse Event","description":"A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"8.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Drug-related Adverse Event","description":"The investigator was to determine if an AE had a reasonable possibility of a relationship to the study drug. The percentage of participants with any drug-related AE was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":null},{"groupId":"OG001","value":"32.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Drug-related Serious Adverse Event","description":"The percentage of participants with any drug-related SAE was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event","description":"The percentage of participants who discontinued study treatment due to an AE was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 48","description":"The percentage of participants in each arm achieving HIV-1 RNA levels \\<40 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) \"snapshot\" approach and all missing data were considered treatment failures, regardless of the reason.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"79.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 96","description":"The percentage of participants in each arm achieving HIV-1 RNA levels \\<40 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) \"snapshot\" approach and all missing data were considered treatment failures, regardless of the reason.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","spread":null},{"groupId":"OG001","value":"64.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":45,"n":383},"commonTop":["Diarrhoea","Nasopharyngitis","Headache","Nausea","Upper respiratory tract infection"]}}}